HIV treatment for children to be produced for under one dollar a day

Geneva, Switzerland – 29 November 2019
Unitaid and DNDi celebrate partnership with Cipla on World AIDS Day
The Indian pharmaceutical company Cipla has announced their commitment to price the ground-breaking new product Quadrimune, a “4‑in‑1” treatment for young children with HIV, at below a dollar a day. Quadrimune is currently under review by the US Food and Drug Administration (FDA) for use in children between 3 and 25 kg bodyweight.

Public-private partnership launched to develop new drugs for roundworm infections

Geneva – 28 November 2019
“Pan-nematode” drug development platform is part of Europe’s Horizon 2020 programme
A new consortium of research institutes, universities, not-for-profit organizations, and pharmaceutical companies has teamed up to develop novel drugs for infections caused by parasitic worms (helminths), a debilitating group of diseases that includes river blindness, lymphatic filariasis, as well as infection with hookworm and whipworm, which together affect close to a billion people.

DNDi receives $29 million to fast-track the development of drugs to help eliminate sleeping sickness and river blindness

Geneva/Seattle – 25  November 2019

DNDi has been awarded $29.2 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – $15 million) and river blindness (onchocerciasis – $14.2 million) by the Bill & Melinda Gates Foundation These two parasitic diseases could be eliminated if new patient care tools are brought to bear.

Study shows that African eye worm threatens elimination of river blindness

Washington DC, USA – 20 November 2019
Over four million people will be infected with river blindness in 2025 in areas where African eye worm is present, according to new modelling
Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or ‘African eye worm’, according to a study published in Clinical Infectious Diseases.

Not-for-profit research and development can address deadly market failure for neglected patients, paper shows

Berlin, Germany – 30 October 2019
15 years of an ‘experiment in innovation’ to discover and develop affordable new treatments in the public interest
In its first 15 years, DNDi has proven that not-for-profit R&D can deliver effective and affordable new treatments to help fill the drug development pipeline for neglected diseases, an area that was suffering from a deadly lack of attention when the organization was created in 2003, according to a new report released today at the two-day DNDi & Founders’ Symposium in Berlin, Germany.

The French development agency AFD renews its support for the Drugs for Neglected Diseases initiative (DNDi) in researching and developing treatments for neglected tropical diseases

Paris, France – 18 October 2019
Bertrand Walckenaer, Deputy CEO of the Agence Française de Développement (AFD), and Dr Bernard Pécoul, Executive Director of DNDi, signed an agreement today for a project to support the research and development of treatments for neglected tropical diseases. Implementing a strategy to develop suitable, affordable, and safe treatments is a major international challenge; more than one billion people in 149 countries are affected by these diseases. This project is funded by a EUR 8 million grant.

Lack of awareness of Chagas disease in the US leading to unnecessary deaths in vulnerable immigrant communities

New York/Los Angeles – 26 September 2019
New DNDi/CECD/MSF paper published in PLOS Neglected Tropical Diseases on the “silent killer” Chagas disease
Fear, stigma, gaps in the health system, and lack of awareness in the medical community are among the barriers keeping the most vulnerable from accessing essential care for Chagas disease, a leading cause of heart disease in the Americas, according to a paper published today by the not-for-profit drug development organization DNDi, the Center of Excellence for Chagas Disease, and the international medical humanitarian organization MSF.

La cuvée 2018 de la ‘Vigne des Nations’ de la République et canton de Genève dédiée à DNDi en reconnaissance de son travail auprès des patients les plus négligés

Genève, Suisse – 15 Septembre 2019
Après avoir reçu le Prix de l’Innovation 2017 de Genève, DNDi est aujourd’hui honoré par la République et canton de Genève, qui lui dédie la cuvée 2018 de la ‘Vigne des Nations’. Cette récompense salue l’engagement de l’organisation internationale à but non lucratif basée à Genève pour le développement de nouveaux traitements pour les populations les plus négligées atteintes de maladies telles que la maladie du sommeil, le mycétome, la leishmaniose, la maladie de Chagas, les maladies liées aux vers filaires, le VIH/SIDA pédiatrique et l’hépatite C.

Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows

Geneva/New Delhi – 22 July 2019
Results show that a skin condition known as post-kala-azar dermal leishmaniasis (PKDL) could be a threat to elimination of leishmaniasis in South Asia
The results of an innovative “infectivity” study conducted by DNDi and the International Centre for Diarrhoeal Disease Research, Bangladesh confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known as PKDL.

Nationwide hepatitis C screening campaign initiated by the Malaysian Ministry of Health

Kuala Lumpur – 17 July 2019
Supported by Drugs for Neglected Diseases initiative & Foundation for Innovative New Diagnostics, campaign seeks to find the “missing millions” for this silent but curable disease
FIND and DNDi are partnering with the Ministry of Health in Malaysia to launch the country’s biggest-ever screening initiative for the hepatitis C virus.

Following 110 years of neglect, an official day for Chagas disease is declared

Geneva, Switzerland – 24 May 2019
The delegates at the World Health Assembly (WHA) have today approved the creation of a World Chagas Day. People affected by Chagas worldwide celebrate this important step in fighting for recognition of this neglected disease.
The International Federation of People Affected by Chagas Disease (FINDECHAGAS) today celebrates the creation of the World Day of People Affected by Chagas at the 72nd World Health Assembly (WHA) in Geneva, Switzerland.

DNDi and Atomwise collaborate to advance drug development using AI for neglected diseases

Geneva, Switzerland and San Francisco, USA – 16 April 2019
Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development
Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and DNDi, a not-for-profit research and development organization working to deliver new treatments for neglected diseases, today announced that promising drug-like compounds have been discovered in a programme to develop first-in-class treatments for Chagas disease. The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards programme.

Chagas disease: the time is now to end 110 years of neglect

Rio de Janeiro – 11 April 2019
The people affected by Chagas disease will claim this 14th of April as World Chagas Day in the hope of increasing global awareness, building on the progress already made against this disease, which has been neglected for more than a century
The International Federation of Associations of People Affected by Chagas disease (FINDECHAGAS) has launched an online petition through the platform change.org in support of the official declaration of April 14th as their World Day. This proposal will be tabled at the 72nd World Health Assembly, to be held in Geneva at the end of May 2019. The particular date has been chosen because on that same day, 110 years ago, the Brazilian doctor Carlos Chagas confirmed the first case of the disease in a child, called Berenice Soares.

GARDP set up as independent legal entity

Geneva, Switzerland – 2 April 2019
Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR
GARDP is now an independent legal entity following a successful three-year incubation, hosted by DNDi. During this time, GARDP has already begun working with partners to develop antibiotics to tackle drug-resistant infections which pose a threat to global health and development, including the achievement of the Sustainable Development Goals.

Study shows dramatically shorter treatment for Chagas disease could be just as effective, and significantly safer

Barcelona/Rio de Janeiro – 14 March 2019
Results could help remove one of the barriers to treatment scale up and bring new hope for people with Chagas disease
A two-week treatment course for adult patients with chronic Chagas disease showed, when compared to placebo, similar efficacy and significantly fewer side effects than the standard treatment duration of eight weeks, according to the results of a clinical trial in Bolivia led by DNDi.

Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis

London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.

Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo

Paris/Geneva – 30 January 2019
Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis, more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC). This approval paves the way for the distribution of fexinidazole in endemic countries this year, with another submission planned in Uganda.